UCB's Global Corporate Website


Evenity logo

In Europe, EVENITY® (romosozumab) is indicated in the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.


▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.